Related Experiment Video
Updated: May 17, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters
Gaelle Haddad1, Junyu Guo1, Yin Xi1
1Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract:
BACKGROUNDThe relationship between molecular subgroups in clear-cell renal cell carcinoma (ccRCC) and metastatic tropism is poorly understood.METHODSWe analyzed over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 phase II clinical trial, where patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.RESULTSAngiogenic tumors (clusters 1 and 2) had a higher rate of pancreatic (21% vs. 6.9%; P = 0.002) and lower absolute number of lymph node (2.5 vs. 4.2; P = 0.006) metastases. In contrast, proliferative tumors (clusters 4 and 5) exhibited a higher absolute number of lymph node metastases (5.5 vs. 3.5; P = 0.019). Patients with pancreatic metastases receiving sunitinib had higher odds of overall response (OR, 7.13; 95% CI, 1.81-28.07; P = 0.0049) and longer progression-free survival than those without pancreatic metastases (P = 0.02).CONCLUSIONccRCC metastatic tropism relates to molecular clusters that predict response to therapy for tumors that metastasize to the pancreas.TRIAL REGISTRATIONClinicalTrials.gov NCT01984242FUNDINGNIH grants R01CA154475 and P50CA196516.
Insights
Clear-cell renal cell carcinoma (ccRCC) molecular subgroups influence where cancer spreads. Angiogenic ccRCC tumors favor pancreatic spread, while proliferative tumors favor lymph node spread, impacting treatment response.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis
Background:
- The metastatic patterns of clear-cell renal cell carcinoma (ccRCC) subtypes are not well understood.
- Identifying these patterns can inform targeted therapies.
Purpose of the Study:
- To investigate the relationship between molecular subgroups of ccRCC and their metastatic tropism.
- To determine if metastatic patterns correlate with treatment response.
Main Methods:
- Analysis of over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 trial.
- Patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.
Main Results:
- Angiogenic ccRCC tumors (clusters 1 and 2) showed a higher incidence of pancreatic metastases (21% vs. 6.9%) and fewer lymph node metastases.
- Proliferative ccRCC tumors (clusters 4 and 5) showed a higher number of lymph node metastases.
- Patients with pancreatic metastases receiving sunitinib had improved overall response and progression-free survival.
Conclusions:
- ccRCC metastatic tropism is linked to specific molecular subgroups.
- These molecular subgroups can predict treatment response, particularly for pancreatic metastases.
More Related Videos
05:17Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
